Bevacizumab Biosimilars Global Market Report 2023

Description

“Bevacizumab Biosimilars Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on bevacizumab biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for bevacizumab biosimilars? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The bevacizumab biosimilars market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Product: Avastin; Mvasi; Zirabev; Aybintio; Other Products
2) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy; Other Distribution Channels
3) By Application: Colorectal Cancer; Non-small Cell Lung Cancer; Glioblastoma; Renal Cell Carcinoma; Cervical Cancer; Ovarian Cancer
Companies Mentioned: Hetero Drugs Ltd.; Amgen Inc.; Biocon Ltd.; Mylan Inc.; BioXpress Therapeutics SA
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the bevacizumab biosimilars market are: Hetero Drugs Ltd., Amgen Inc., Biocon Ltd., Mylan Inc., BioXpress Therapeutics SA, Celltrion Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Samsung Bioepis Co. Ltd., mAbxience SA, Aurobindo Pharma Ltd., Abbvie Inc., Allergan Plc., Reliance lifesciences Pvt. Ltd., Beaconpharma Ltd., Celgene Corporation Co. Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., F. Hoffmann-La Roche Ltd., and Genentech Inc.

The global bevacizumab biosimilars market is expected to grow from $1.31 billion in 2022 to $1.43 billion in 2023 at a compound annual growth rate (CAGR) of 9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The bevacizumab biosimilars market is expected to reach $1.93 billion in 2027 at a CAGR of 7.9%.

The bevacizumab biosimilars market consists of sales of byvasda, cizumab, alymsys, bevax, and cyramza. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Bevacizumab biosimilars are a type of medication that is highly similar to a reference biologic drug called bevacizumab. It is commonly used to inhibit the growth of new blood vessels in tumors, thereby slowing down their progression.

North America was the largest region in the bevacizumab biosimilars market in 2022. The regions covered in bevacizumab biosimilars report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main types of bevacizumab biosimilar products are avastin, mvasi, zirabev, aybintio, and others. Avastin is the brand name for the original biological drug bevacizumab, referring to an anti-angiogenic therapy that inhibits the formation of new blood vessels. They are available in various distribution channels, such as hospital pharmacies, online pharmacies, retail pharmacies, and others. They are used for various applications such as colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, and ovarian cancer.

The rising prevalence of cancer cases is expected to propel the growth of the bevacizumab biosimilars market going forward. Cancer incidence refers to the number of new cancer cases in a specific population for a given period. Bevacizumab is a biologic that inhibits tumor angiogenesis, which can lead to tumor shrinkage and growth inhibition, and it is comparable to reference biologics in terms of efficacy and safety in treating patients with advanced non-small cell lung cancer or metastatic colorectal cancer. For instance, in 2021, According to the American cancer society, 1.8 million new cancer cases were diagnosed in 2020. Furthermore, according to September 2020 data published by the National Cancer Institute, a US-based government agency part of the National Institutes of Health, 1,806,590 new cancer cases were recorded, indicating that 43% of all cancer diagnosed in men in the United States in 2020, up from 1,752,735 in the previous year, i.e., 2019. Therefore, the rising prevalence of cancer cases drives the bevacizumab biosimilars market.

Product innovation has emerged as a key trend gaining popularity in the bevacizumab biosimilars market. Major market players are concentrating their efforts on creating innovative products to strengthen their position in the market. For instance, in May 2022, Viatris, a US-based pharmaceutical company, and Biocon Biologics, a US-based pharmaceutical company, launched a biosimilar called Abevmy® (bevacizumab), which is a biosimilar similar to Roche's Avastin® (bevacizumab). Abevmy has received approval from Health Canada for use across four oncology indications. The product offers efficacy, safety, and quality similar to the reference biologic, as it is a synthesized humanized monoclonal antibody (MA) that binds to and neutralizes the biologic action of human vascular endothelial growth factor (VEGF).

In November 2022, Biocon Biologics Ltd., an India-based firm and subsidiary of Biocon Ltd., that manufactures biopharmaceuticals acquired Viatris Inc.'s global biosimilars business for an undisclosed amount. With this acquisition, Biocon Biologics aims to further strengthen its position in the biosimilars market. Viatris Inc. is a US-based pharmaceutical and healthcare company that deals in medicines for major therapeutic areas including cancer, including Bevacizumab.

The countries covered in the bevacizumab biosimilars market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The bevacizumab biosimilar market research report is one of a series of new reports from The Business Research Company that provides bevacizumab biosimilar market statistics, including bevacizumab biosimilar industry global market size, regional shares, competitors with a bevacizumab biosimilar market share, detailed bevacizumab biosimilar market segments, market trends, and opportunities, and any further data you may need to thrive in the bevacizumab biosimilar industry. This bevacizumab biosimilar market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Product Code: r7938

1. Executive Summary

2. Bevacizumab Biosimilars Market Characteristics

3. Bevacizumab Biosimilars Market Trends And Strategies

4. Bevacizumab Biosimilars Market - Macro Economic Scenario

4.1. COVID-19 Impact On Bevacizumab Biosimilars Market
4.2. Ukraine-Russia War Impact On Bevacizumab Biosimilars Market
4.3. Impact Of High Inflation On Bevacizumab Biosimilars Market

5. Bevacizumab Biosimilars Market Size And Growth

5.1. Global Bevacizumab Biosimilars Historic Market, 2017-2022, $ Billion
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints On The Market
5.2. Global Bevacizumab Biosimilars Forecast Market, 2022-2027F, 2032F, $ Billion
- 5.2.1. Drivers Of The Market
- 5.2.2. Restraints On the Market

6. Bevacizumab Biosimilars Market Segmentation

6.1. Global Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Avastin
Mvasi
Zirabev
Aybintio
Other Products
6.2. Global Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Other Distribution Channels
6.3. Global Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Colorectal Cancer
Non-small Cell Lung Cancer
Glioblastoma
Renal Cell Carcinoma
Cervical Cancer
Ovarian Cancer

7. Bevacizumab Biosimilars Market Regional And Country Analysis

7.1. Global Bevacizumab Biosimilars Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Bevacizumab Biosimilars Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Bevacizumab Biosimilars Market

8.1. Asia-Pacific Bevacizumab Biosimilars Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
8.3. Asia-Pacific Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Bevacizumab Biosimilars Market

9.1. China Bevacizumab Biosimilars Market Overview
9.2. China Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
9.3. China Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Bevacizumab Biosimilars Market

10.1. India Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
10.2. India Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Bevacizumab Biosimilars Market

11.1. Japan Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
11.2. Japan Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Bevacizumab Biosimilars Market

12.1. Australia Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
12.2. Australia Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Bevacizumab Biosimilars Market

13.1. Indonesia Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
13.2. Indonesia Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Bevacizumab Biosimilars Market

14.1. South Korea Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
14.2. South Korea Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Bevacizumab Biosimilars Market

15.1. Western Europe Bevacizumab Biosimilars Market Overview
15.2. Western Europe Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
15.3. Western Europe Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Bevacizumab Biosimilars Market

16.1. UK Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
16.2. UK Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Bevacizumab Biosimilars Market

17.1. Germany Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
17.2. Germany Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Bevacizumab Biosimilars Market

18.1. France Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
18.2. France Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe Bevacizumab Biosimilars Market

19.1. Eastern Europe Bevacizumab Biosimilars Market Overview
19.2. Eastern Europe Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
19.3. Eastern Europe Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia Bevacizumab Biosimilars Market

20.1. Russia Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
20.2. Russia Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America Bevacizumab Biosimilars Market

21.1. North America Bevacizumab Biosimilars Market Overview
21.2. North America Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
21.3. North America Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA Bevacizumab Biosimilars Market

22.1. USA Bevacizumab Biosimilars Market Overview
22.2. USA Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
22.3. USA Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America Bevacizumab Biosimilars Market

23.1. South America Bevacizumab Biosimilars Market Overview
23.2. South America Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
23.3. South America Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil Bevacizumab Biosimilars Market

24.1. Brazil Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
24.2. Brazil Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East Bevacizumab Biosimilars Market

25.1. Middle East Bevacizumab Biosimilars Market Overview
25.2. Middle East Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
25.3. Middle East Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa Bevacizumab Biosimilars Market

26.1. Africa Bevacizumab Biosimilars Market Overview
26.2. Africa Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
26.3. Africa Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Bevacizumab Biosimilars Market Competitive Landscape And Company Profiles

27.1. Bevacizumab Biosimilars Market Competitive Landscape
27.2. Bevacizumab Biosimilars Market Company Profiles
- 27.2.1. Hetero Drugs Ltd.
  - 27.2.1.1. Overview
  - 27.2.1.2. Products and Services
  - 27.2.1.3. Strategy
  - 27.2.1.4. Financial Performance
- 27.2.2. Amgen Inc.
  - 27.2.2.1. Overview
  - 27.2.2.2. Products and Services
  - 27.2.2.3. Strategy
  - 27.2.2.4. Financial Performance
- 27.2.3. Biocon Ltd.
  - 27.2.3.1. Overview
  - 27.2.3.2. Products and Services
  - 27.2.3.3. Strategy
  - 27.2.3.4. Financial Performance
- 27.2.4. Mylan Inc.
  - 27.2.4.1. Overview
  - 27.2.4.2. Products and Services
  - 27.2.4.3. Strategy
  - 27.2.4.4. Financial Performance
- 27.2.5. BioXpress Therapeutics SA
  - 27.2.5.1. Overview
  - 27.2.5.2. Products and Services
  - 27.2.5.3. Strategy
  - 27.2.5.4. Financial Performance

28. Key Mergers And Acquisitions In The Bevacizumab Biosimilars Market

29. Bevacizumab Biosimilars Market Future Outlook and Potential Analysis

30. Appendix

30.1. Abbreviations
30.2. Currencies
30.3. Historic And Forecast Inflation Rates
30.4. Research Inquiries
30.5. The Business Research Company
30.6. Copyright And Disclaimer